1.61
+0.03(+1.90%)
Currency In USD
| Previous Close | 1.58 |
| Open | 1.58 |
| Day High | 1.68 |
| Day Low | 1.57 |
| 52-Week High | 21.95 |
| 52-Week Low | 0.89 |
| Volume | 133,484 |
| Average Volume | 5.85M |
| Market Cap | 11.66M |
| PE | 0.81 |
| EPS | 1.99 |
| Moving Average 50 Days | 1.8 |
| Moving Average 200 Days | 3.11 |
| Change | 0.03 |
If you invested $1000 in Mustang Bio, Inc. (MBIO) since IPO date, it would be worth $0.22 as of September 18, 2025 at a share price of $1.61. Whereas If you bought $1000 worth of Mustang Bio, Inc. (MBIO) shares 5 years ago, it would be worth $0.55 as of September 18, 2025 at a share price of $1.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
GlobeNewswire Inc.
Jul 07, 2025 12:30 PM GMT
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively Preclinical data
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
GlobeNewswire Inc.
Mar 05, 2025 9:15 PM GMT
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained comp
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
GlobeNewswire Inc.
Feb 27, 2025 9:05 PM GMT
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures